DRI Healthcare Trust - Asset Resilience Ratio
DRI Healthcare Trust (DHT-U) has an Asset Resilience Ratio of 13.91% as of March 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read DHT-U total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (None–None)
This chart shows how DRI Healthcare Trust's Asset Resilience Ratio has changed over time. See DHT-U net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down DRI Healthcare Trust's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see DRI Healthcare Trust market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $125.67 Million | 13.91% |
| Total Liquid Assets | $125.67 Million | 13.91% |
Asset Resilience Insights
- Moderate Liquidity: DRI Healthcare Trust has 13.91% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
DRI Healthcare Trust Industry Peers by Asset Resilience Ratio
Compare DRI Healthcare Trust's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI |
Drug Manufacturers - Specialty & Generic | 1.54% |
|
Yunnan Baiyao Group Co Ltd
SHE:000538 |
Drug Manufacturers - Specialty & Generic | 8.38% |
|
Cipla Limited
NSE:CIPLA |
Drug Manufacturers - Specialty & Generic | 20.75% |
|
Alkem Laboratories Limited
NSE:ALKEM |
Drug Manufacturers - Specialty & Generic | 31.91% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.92% |
|
Guobang Pharma Ltd
SHG:605507 |
Drug Manufacturers - Specialty & Generic | 11.00% |
Annual Asset Resilience Ratio for DRI Healthcare Trust (None–None)
The table below shows the annual Asset Resilience Ratio data for DRI Healthcare Trust.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| No yearly data available. | ||||
About DRI Healthcare Trust
DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas. The company was incorporated in 2020 and is headquartered in Toronto, Canada.